|
|||||
|
|
Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials |
|
| Institution: | 1. Division of Gastroenterology, John T. Milliken Department of Medicine, Washington University School of Medicine, St Louis, Missouri;2. Georgetown University School of Medicine, Washington, DC;3. Duke University Medical Center and Durham Veterans Affairs Health Care System, Durham, North Carolina;4. University of Connecticut Health Center, Farmington, Connecticut;5. Mayo Clinic, Rochester, Minnesota;6. Otsuka Pharmaceutical Development & Commercialization, Inc, Rockville, Maryland |
| Abstract: |  |
| Keywords: | Autosomal dominant polycystic kidney disease (ADPKD) tolvaptan drug-induced liver injury (DILI) clinical trial liver safety Hy’s Law alanine aminotransferase (ALT) aspartate aminotransferase (AST) hepatic events drug rechallenge JYNARQUE |
| 本文献已被 ScienceDirect 等数据库收录！ | |